Biological Insight and Recent Advancement in the Treatment of Neuroblastoma
International Journal of Molecular Sciences · 09.05.2023 · 24 (10) · 8470
DOI: 10.3390/ijms24108470 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.05.2023. Verfasst von Zoriamin Rivera und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neuroblastoma. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
One of the most frequent solid tumors in children is neuroblastoma, which has a variety of clinical behaviors that are mostly influenced by the biology of the tumor. Unique characteristics of neuroblastoma includes its early age of onset, its propensity for spontaneous tumor regression in newborns, and its high prevalence of metastatic disease at diagnosis in individuals older than 1 year of age. Immunotherapeutic techniques have been added to the previously enlisted chemotherapeutic treatments as therapeutic choices. A groundbreaking new treatment for hematological malignancies is adoptive cell therapy, specifically chimeric antigen receptor (CAR) T cell therapy. However, due to the immunosuppressive nature of the tumor microenvironment (TME) of neuroblastoma tumor, this treatment approach faces difficulties. Numerous tumor-associated genes and antigens, including the MYCN proto-oncogene (MYCN) and disialoganglioside (GD2) surface antigen, have been found by the molecular analysis of neuroblastoma cells. The MYCN gene and GD2 are two of the most useful immunotherapy findings for neuroblastoma. The tumor cells devise numerous methods to evade immune identification or modify the activity of immune cells. In addition to addressing the difficulties and potential advancements of immunotherapies for neuroblastoma, this review attempts to identify important immunological actors and biological pathways involved in the dynamic interaction between the TME and immune system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
- Division of Surgical Oncology, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
ORCID-Profile: Kajal H Gupta
Zitieren
APA
Rivera, Z., Escutia, C., Madonna, M. B., & Gupta, K. H. (2023). Biological Insight and Recent Advancement in the Treatment of Neuroblastoma. International Journal of Molecular Sciences, 24(10), 8470. https://doi.org/10.3390/ijms24108470
Vancouver
Rivera Z, Escutia C, Madonna MB, Gupta KH. Biological Insight and Recent Advancement in the Treatment of Neuroblastoma. International Journal of Molecular Sciences. 2023;24(10):8470. doi:10.3390/ijms24108470
BibTeX
@article{Rivera2023,
author = {Rivera, Zoriamin and Escutia, Carlos and Madonna, Mary Beth and Gupta, Kajal H},
title = {Biological Insight and Recent Advancement in the Treatment of Neuroblastoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {10},
pages = {8470},
doi = {10.3390/ijms24108470}
}
EUVIMED